

RECEIVED  
CENTRAL FAX CENTER  
OCT 18 2006

AMENDMENTS TO THE CLAIMS

1-92. (Canceled).

93. (New) A compound represented by Formula VIII:

R1-X1-X2-X3-R2

wherein:

X1 is O, Ala, Gly,  $\beta$ -Ala, Tyr, D-Tyr, Asp, or hydroxyacetyl;

X2 is O, Ala-Gly-T4c-Pro, Ala-Sar-Hyp-Pro, Ala-6ring-, Ala-Asn, D-Asn-D-Ala, D-Asn,  $\gamma$ Abu, Gly, Ala, D-Ala,  $\beta$ -Ala, Pamb, Asn, or hydroxyacetyl;

X3 is Tyr, D-Tyr, Gly, Pamb, or Phe;

R1 is H or Ac;

and pharmaceutically acceptable salts thereof,

provided that X1 and X2 are not both O; and wherein said compound has an amide formed with the C-terminal carboxylic acid, or wherein the C-terminal amino acid of said compound exists as the free carboxylic acid.

94. (New) The compound of claim 93, wherein X3 is Tyr.

95. (New) The compound of claim 93, wherein X2 is Asn.

96. (New) The compound of claim 93, wherein X2 is Gly.

97. (New) The compound of claim 93, wherein X3 is Tyr and X2 is Asn or Gly.

98. (New) The compound of claim 93, wherein X1 is hydroxyacetyl and R1 is H.

99. (New) The compound of claim 93, wherein X3 is Tyr, X2 is Asn or Gly, X1 is hydroxyacetyl, and R1 is H.

100. (New) The compound of claim 99, wherein X2 is Asn.

101. (New) The compound of claim 99, wherein R2 is OH.

102. (New) The compound of claim 99, wherein R2 is NH<sub>2</sub>.

103. (New) The compound of claim 93, wherein said compound is selected from the group consisting of Ac-hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, Ac-hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Gly-Tyr-NH<sub>2</sub>, hydroxyacetyl-Gly-Tyr-OH, Ac-hydroxyacetyl-Gly-Tyr-NH<sub>2</sub>, and Ac-hydroxyacetyl-Gly-Tyr-OH; or a pharmaceutically acceptable salt thereof.

104. (New) The compound of claim 93, wherein said compound is hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, or a pharmaceutically acceptable salt thereof.

105. (New) A pharmaceutical composition comprising:

- (a) a compound of claim 93 or a pharmaceutically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or diluent.

106. (New) The pharmaceutical composition of claim 105, wherein the compound selected from the group consisting of Ac-hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, Ac-hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Gly-Tyr-NH<sub>2</sub>, hydroxyacetyl-Gly-Tyr-OH, Ac-hydroxyacetyl-Gly-Tyr-NH<sub>2</sub>, and Ac-hydroxyacetyl-Gly-Tyr-OH; or a pharmaceutically acceptable salt thereof.

107. (New) The pharmaceutical composition of claim 105, wherein said compound is hydroxyacetyl-Asn-Tyr-NH<sub>2</sub>, or a pharmaceutically acceptable salt thereof.

108. (New) The pharmaceutical composition of claim 105, wherein said composition is in a form suitable for oral or parenteral administration.

109. (New) The pharmaceutical composition of claim 108, wherein said form  
suitable for oral administration is an enteric tablet.